MX2016008729A - Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. - Google Patents
Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma.Info
- Publication number
- MX2016008729A MX2016008729A MX2016008729A MX2016008729A MX2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A MX 2016008729 A MX2016008729 A MX 2016008729A
- Authority
- MX
- Mexico
- Prior art keywords
- clomipramine
- preparation
- pharmaceutical composition
- composition containing
- method therefor
- Prior art date
Links
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 title abstract 4
- 229960004606 clomipramine Drugs 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 238000002360 preparation method Methods 0.000 title 1
- 239000004480 active ingredient Substances 0.000 abstract 3
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 abstract 2
- FGBFEFJZYZDLSZ-UHFFFAOYSA-N 5,7-dimethoxy-2,3-dimethyl-2,3-dihydroinden-1-one Chemical compound COC1=CC(OC)=CC2=C1C(=O)C(C)C2C FGBFEFJZYZDLSZ-UHFFFAOYSA-N 0.000 abstract 1
- 229960001564 clomipramine hydrochloride Drugs 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229960003310 sildenafil Drugs 0.000 abstract 1
- 229960002639 sildenafil citrate Drugs 0.000 abstract 1
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 abstract 1
- 238000005550 wet granulation Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención proporciona una formulación farmacéutica que comprende clomipramina o su sal farmacéuticamente aceptable (preferiblemente, hidrocloruro de clomipramina) como el primer ingrediente activo, y sildenafil o su sal farmacéuticamente aceptable (preferiblemente, citrato de sildenafil) como el segundo ingrediente activo, en donde la estabilidad de la clomipramina es mejorada, y un método para fabricar esta formulación farmacéutica. En particular, la presente invención proporciona una formulación farmacéutica que comprende los dos ingredientes activos anteriores y es fabricada mediante el uso de un método de granulación en húmedo, en donde la estabilidad de la clomipramina es mejorada, y un método para la fabricación de esta formulación farmacéutica.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130168702 | 2013-12-31 | ||
| PCT/KR2014/012969 WO2015102337A1 (ko) | 2013-12-31 | 2014-12-29 | 클로미프라민 함유 약학 조성물 및 이의 제조 방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016008729A true MX2016008729A (es) | 2017-02-28 |
| MX381175B MX381175B (es) | 2025-03-12 |
Family
ID=53493626
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000769A MX394413B (es) | 2013-12-31 | 2014-12-29 | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma |
| MX2016008729A MX381175B (es) | 2013-12-31 | 2014-12-29 | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021000769A MX394413B (es) | 2013-12-31 | 2014-12-29 | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US10045944B2 (es) |
| EP (1) | EP3090732B1 (es) |
| KR (3) | KR20150079449A (es) |
| CN (1) | CN105899193A (es) |
| BR (1) | BR112016015175A2 (es) |
| ES (1) | ES2988594T3 (es) |
| MX (2) | MX394413B (es) |
| WO (1) | WO2015102337A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX394413B (es) * | 2013-12-31 | 2025-03-24 | Ctc Bio Inc | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma |
| CN108126203A (zh) * | 2018-01-05 | 2018-06-08 | 黄平 | 一种药物组合物及其药物递送系统与用途 |
| US11957692B2 (en) | 2022-05-23 | 2024-04-16 | National Institute Of Immunology | Clomipramine for the treatment of Alzheimer's Disease |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403597B1 (en) | 1997-10-28 | 2002-06-11 | Vivus, Inc. | Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation |
| US20020091129A1 (en) | 2000-11-20 | 2002-07-11 | Mitradev Boolell | Treatment of premature ejaculation |
| US6495154B1 (en) * | 2000-11-21 | 2002-12-17 | Vivus Inc. | On demand administration of clomipramine and salts thereof to treat premature ejaculation |
| US6863901B2 (en) | 2001-11-30 | 2005-03-08 | Collegium Pharmaceutical, Inc. | Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration |
| EP1896076A2 (en) * | 2005-06-27 | 2008-03-12 | Daniel Drai | Compositions and methods for enhancement of sexual function |
| JP2009517346A (ja) * | 2005-11-28 | 2009-04-30 | イメイジノット ピーティーワイ エルティーディー | 治療用化合物の経口送達系 |
| CA2722845A1 (en) * | 2008-05-19 | 2009-11-26 | Yuhan Corporation | Pharmaceutical composition for the treatment of premature ejaculation |
| BR112013033475A2 (pt) | 2011-06-28 | 2017-12-19 | Ctc Bio Inc | composição farmacêutica para tratamento, prevenção ou melhora da ejaculação precoce e método para tratamento, prevenção ou melhora da ejaculação precoce |
| MX394413B (es) * | 2013-12-31 | 2025-03-24 | Ctc Bio Inc | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma |
-
2014
- 2014-12-29 MX MX2021000769A patent/MX394413B/es unknown
- 2014-12-29 US US15/109,198 patent/US10045944B2/en active Active
- 2014-12-29 ES ES14876267T patent/ES2988594T3/es active Active
- 2014-12-29 CN CN201480071923.4A patent/CN105899193A/zh active Pending
- 2014-12-29 EP EP14876267.7A patent/EP3090732B1/en active Active
- 2014-12-29 MX MX2016008729A patent/MX381175B/es unknown
- 2014-12-29 BR BR112016015175A patent/BR112016015175A2/pt not_active Application Discontinuation
- 2014-12-29 WO PCT/KR2014/012969 patent/WO2015102337A1/ko not_active Ceased
- 2014-12-29 KR KR1020140192044A patent/KR20150079449A/ko not_active Ceased
-
2018
- 2018-07-06 US US16/028,558 patent/US10512610B2/en active Active
-
2021
- 2021-08-13 KR KR1020210107677A patent/KR102357423B1/ko active Active
-
2022
- 2022-01-25 KR KR1020220011066A patent/KR102527999B1/ko active Active
Also Published As
| Publication number | Publication date |
|---|---|
| BR112016015175A2 (pt) | 2017-08-08 |
| MX2021000769A (es) | 2022-07-29 |
| US20180311170A1 (en) | 2018-11-01 |
| KR20150079449A (ko) | 2015-07-08 |
| EP3090732A4 (en) | 2017-06-28 |
| KR20220017458A (ko) | 2022-02-11 |
| US10512610B2 (en) | 2019-12-24 |
| KR102527999B1 (ko) | 2023-05-02 |
| CN105899193A (zh) | 2016-08-24 |
| EP3090732A1 (en) | 2016-11-09 |
| KR20210104618A (ko) | 2021-08-25 |
| ES2988594T3 (es) | 2024-11-21 |
| MX381175B (es) | 2025-03-12 |
| EP3090732B1 (en) | 2024-07-24 |
| MX394413B (es) | 2025-03-24 |
| WO2015102337A1 (ko) | 2015-07-09 |
| KR102357423B1 (ko) | 2022-02-08 |
| US10045944B2 (en) | 2018-08-14 |
| US20160324789A1 (en) | 2016-11-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| CR20150628A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| CR20150629A (es) | Compuestos químicos | |
| NI201700011A (es) | 2-(morfolin-4-il)-1,7-naftiridinas. | |
| CR20150480A (es) | Composición farmacéutica de clorhidrato de s-cetamina | |
| NI201500135A (es) | Composición farmacéutica de hidrocloruro de s-ketamina | |
| ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
| DOP2015000170A (es) | Compuestos químicos | |
| CR20170003A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| CO6640216A2 (es) | Composiciones farmacéuticas que comprenden hidromorfona y naloxona | |
| CO2017006958A2 (es) | Formulaciones farmacéuticas que comprenden cangrelor de alta pureza y métodos para la preparación y uso de los mismos | |
| CO2019002246A2 (es) | Compuesto heterocíclico nitrogenado bicíclico | |
| GT201700016A (es) | [1,2,4] triazolo [4,3 -b] piridazinas para su uso en el tratamiento de enfermedades proliferativas | |
| CL2020001277A1 (es) | Derivados de piridinona y su uso como inhibidores selectivos de alk-2. | |
| MX2021000769A (es) | Composicion farmaceutica que contiene clomipramina y metodo de preparacion de la misma. | |
| UY36958A (es) | Compuestos para administración intracelular | |
| EA201500366A1 (ru) | Применение 1-адамантилетилокси-3-морфолино-2-пропанола или его фармацевтически приемлемых солей в фармацевтических композициях в качестве нейроретинопротектора | |
| CL2012002924A1 (es) | Una composicion que contiene como ingrediente activo a perclorato de 4-tioureido-iminometilpiridinio y sustancias farmaceuticamente aceptables; metodo de preparacion; y su uso para el tratamiento y/o la prevencion de todas las formas de tuberculosis pulmonar y extrapulmonar. | |
| PE20150022A1 (es) | Dronedarona para uso en la leishmaniosis, formulaciones y asociaciones para uso en la leishmaniosis | |
| MX2019001701A (es) | Composicion farmaceutica de dosis fija que comprende mometasona y azelastina. | |
| CO2018007821A2 (es) | Formulación de combinación farmacéutica | |
| BR112017009852A2 (pt) | composto, composição, e, usos de um composto | |
| MX383685B (es) | Clonidina y/o derivados de clonidina para uso en la prevención de la lesión de la piel resultante de la radioterapia. | |
| CL2013003665A1 (es) | Compuestos derivados de pirrolotriazinas sustituidas con hidroximetilarilo inhibidores de alk1 quinasas; composición farmacéutica que los comprende; uso en el tratamiento de la degeneración macular relacionada con la edad, neovascularización coroídea, retinopatía diabética y edema macular diabético. | |
| MX2018002449A (es) | Formulaciones de liberacion retardada, metodos de fabricacion y uso de las mismas. |